Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation (Q39990704)

16 September 2017

Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation (English)

1 reference

16 September 2017

0 references

1 reference

7

Cheryl L Willman

1 reference

16 September 2017

Blaine W Robinson

1

1 reference

16 September 2017

Kathryn C Behling

2

1 reference

16 September 2017

Manish Gupta

3

1 reference

16 September 2017

Alena Y Zhang

4

1 reference

16 September 2017

Jonni S Moore

5

1 reference

16 September 2017

Andrew D Bantly

6

1 reference

16 September 2017

Andrew J Carroll

8

1 reference

16 September 2017

Peter C Adamson

9

1 reference

16 September 2017

Jeffrey S Barrett

10

1 reference

16 September 2017

Carolyn A Felix

11

1 reference

16 September 2017

language of work or name

English

0 references

publication date

18 April 2008

1 reference

British Journal of Haematology

16 September 2017

1 reference

16 September 2017

141

1 reference

16 September 2017

6

1 reference

16 September 2017

827-839

1 reference

Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members

16 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Conversion of Bcl-2 to a Bax-like death effector by caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Cell death: critical control points

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Bcl2 retards G1/S cell cycle transition by regulating intracellular ROS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Novel approach for simultaneous evaluation of cell phenotype, apoptosis, and cell cycle using multiparameter flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

CombiTool--a new computer program for analyzing combination experiments with biologically active agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Association of CYP3A4 genotype with treatment-related leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Unlocking the potential of the human genome with RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Resistance of t(4;11) (MLL-AF4 fusion gene) leukemias to stress-induced cell death: possible mechanism for extensive extramedullary accumulation of cells and poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Laying the foundations of programmed cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

From bench to clinic with apoptosis-based therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

BCL-2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia associated with the t(4;11)(q21;q23) translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Panhandle and reverse-panhandle PCR enable cloning of der(11) and der(other) genomic breakpoint junctions of MLL translocations and identify complex translocation of MLL, AF-4, and CDK6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Apoptosis-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Apoptosis-targeted therapies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

BglII-based panhandle and reverse panhandle PCR approaches increase capability for cloning der(II) and der(other) genomic breakpoint junctions of MLL translocations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2008.07100.X

10.1111/J.1365-2141.2008.07100.X

21 January 2018

Identifiers

DOI

1 reference

16 September 2017

1 reference